Develops cell and gene therapies for cancer and rare genetic diseases, focusing on novel approaches to treating hematologic malignancies.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing breakthroughs in cell and gene therapies aimed at potentially curing hematologic cancers, solid tumors, and rare genetic diseases. The company's robust pipeline encompasses gene therapy programs targeting rare genetic disorders, as well as chimeric antigen receptor (CAR) engineered T cell therapies tailored for hematologic malignancies and solid tumors. Notably, Mustang Bio develops MB-107 and MB-207, gene therapy programs addressing X-linked severe combined immunodeficiency, a rare genetic condition that can be fatal without intervention.
Based in Worcester, Massachusetts, Mustang Bio, Inc. was founded in 2015 with a mission to revolutionize treatment options in oncology and genetic diseases. The company's comprehensive portfolio includes CAR T cell therapies such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome, among others. Additionally, Mustang Bio is advancing MB-108, a next-generation oncolytic herpes simplex virus, highlighting its commitment to pioneering innovative therapeutic approaches.
Driven by strategic collaborations and licensing agreements with renowned institutions like Nationwide Children's Hospital and Mayo Clinic, Mustang Bio, Inc. continues to expand its scientific capabilities and therapeutic reach. With a steadfast focus on translating cutting-edge research into clinical applications, the company aims to deliver transformative treatments that offer new hope to patients worldwide.